Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak

Executive Summary

As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space

You may also be interested in...



Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”

Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.

Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”

Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.

Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder

The deal also requires Bristol to make an equity investment of up to $20 million should Alder go public.

Related Content

Topics

UsernamePublicRestriction

Register

PS051712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel